An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine
暂无分享,去创建一个
P. DeInnocentes | R. C. Bird | Bruce F. Smith | F. W. Ginkel | Allison E Church Bird | Joni Lindquist
[1] J. Taylor‐Papadimitriou,et al. MUC1 immunotherapy. , 2010, Immunotherapy.
[2] V. Hespanhol,et al. MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features. , 2009, Veterinary journal.
[3] P. DeInnocentes,et al. Phenotype‐rescue of cyclin‐dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer , 2009, Journal of cellular biochemistry.
[4] D. Curiel,et al. An allogeneic hybrid-cell fusion vaccine against canine mammary cancer. , 2008, Veterinary immunology and immunopathology.
[5] W. Misdorp,et al. Tumors of the Mammary Gland , 2008 .
[6] H. Asanuma,et al. T‐Helper (Th) 1/ Th2 Imbalance in the Peripheral Blood of Dogs with Malignant Tumor , 2007, Microbiology and immunology.
[7] M. Day. Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. , 2007, Veterinary parasitology.
[8] G. Mulcahy,et al. Evaluation of Th1-like, Th2-like and immunomodulatory cytokine mRNA expression in the skin of dogs with immunomodulatory-responsive lymphocytic-plasmacytic pododermatitis. , 2006, Veterinary dermatology.
[9] P. DeInnocentes,et al. Expression and sequence of canine SIRT2 and p53 genes in canine mammary tumour cells - effects on downstream targets Wip1 and p21/Cip1. , 2006, Veterinary and comparative oncology.
[10] P. DeInnocentes,et al. Alterations in CDK1 expression and nuclear/nucleolar localization following induction in a spontaneous canine mammary cancer model , 2006, Journal of cellular biochemistry.
[11] T. Ohno,et al. Cancer immunotherapy using dendritic/tumour‐fusion vaccine induces elevation of serum anti‐nuclear antibody with better clinical responses , 2006, Clinical and experimental immunology.
[12] A. Loukas,et al. Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs. , 2006, Vaccine.
[13] M. Atkins,et al. Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses , 2004, Clinical Cancer Research.
[14] P. DeInnocentes,et al. Characterization of the CDP-like/CTAS-1 binding site in the okadaic acid response element (OARE) of the human CDK1(p34cdc2) promoter. , 2004, Anticancer research.
[15] E. Macewen,et al. Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment , 1990, Cancer and Metastasis Reviews.
[16] J. Raynaud,et al. Animal models for hormone-dependent human breast cancer , 2004, Cancer Chemotherapy and Pharmacology.
[17] P. Boag,et al. Characterisation of humoral immune responses in dogs vaccinated with irradiated Ancylostoma caninum. , 2003, Veterinary immunology and immunopathology.
[18] L. H. Carvalho,et al. IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages , 2002, Nature Medicine.
[19] H. J. Baker,et al. CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. , 2002, Veterinary immunology and immunopathology.
[20] Joanna S Morris,et al. Small Animal Oncology , 2001 .
[21] E. Gilboa,et al. Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA1 , 2001, The Journal of Immunology.
[22] T. Ohno,et al. Antitumor Effect of Immunizations With Fusions of Dendritic and Glioma Cells in a Mouse Brain Tumor Model , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[23] S. Wagner,et al. Management of malignant melanoma: new developments in immune and gene therapy , 2000, Clinical and experimental dermatology.
[24] E. Wagner,et al. Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice , 2000, Cancer Gene Therapy.
[25] Salgaller Ml. American Association for Cancer Research: dendritic cells: strategies and vaccines. April 1-5, 2000, San Francisco, CA, USA. , 2000 .
[26] M. Salgaller. American Association for Cancer Research , 2000, Expert opinion on investigational drugs.
[27] A. Dalgleish,et al. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. , 2000, Biochimica et biophysica acta.
[28] D. Kufe,et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[29] P. Walden. Hybrid cell vaccination for cancer immunotherapy. , 2000, Advances in experimental medicine and biology.
[30] H. O’Neill,et al. Dendritic Cell Immunotherapy for Melanoma , 1999 .
[31] H. O’Neill,et al. Review: dendritic cell immunotherapy for melanoma. , 1999, Cancer biotherapy & radiopharmaceuticals.
[32] S. Nair. Immunotherapy of cancer with dendritic cell-based vaccines , 1998, Gene Therapy.
[33] W. Morrow,et al. Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model , 1998, Gene Therapy.
[34] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[35] J. Timmerman,et al. Melanoma vaccines: Prim and proper presentation , 1998, Nature Medicine.
[36] U. Trefzer,et al. Hybrid cell vaccination in cancer immunotherapy. Recruitment and activation of T cell help for induction of anti tumour cytotoxic T cells. , 1998, Advances in experimental medicine and biology.
[37] R. Steinman,et al. Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors , 1997, The Journal of experimental medicine.
[38] Steinman Rm. Dendritic cells and immune-based therapies. , 1996 .
[39] R. C. Bird,et al. Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. , 1996, American journal of veterinary research.
[40] E. Sartin,et al. Heterogenic properties of clonal cell lines derived from canine mammary carcinomas and sensitivity to tamoxifen and doxorubicin. , 1993, Anticancer research.
[41] R. Henderson,et al. Biologic properties of cell lines derived from canine mammary carcinomas. , 1986, Journal of the National Cancer Institute.
[42] D. Taylor,et al. Factors influencing canine mammary cancer development and postsurgical survival. , 1969, Journal of the National Cancer Institute.
[43] I Iu IUDIN,et al. [Tumors of the mammary gland]. , 1955, Meditsinskaia sestra.